282 related articles for article (PubMed ID: 30358109)
21. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis.
Crotti C; Biggioggero M; Becciolini A; Agape E; Favalli EG
Expert Opin Investig Drugs; 2019 Jul; 28(7):573-581. PubMed ID: 31208237
[No Abstract] [Full Text] [Related]
22. Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
Genovese MC; Braun DK; Erickson JS; Berclaz PY; Banerjee S; Heffernan MP; Carlier H
J Rheumatol; 2016 Feb; 43(2):289-97. PubMed ID: 26669919
[TBL] [Abstract][Full Text] [Related]
23. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
24. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
[TBL] [Abstract][Full Text] [Related]
25. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.
Popa C; Netea MG; Radstake TR; van Riel PL; Barrera P; van der Meer JW
Ann Rheum Dis; 2005 Aug; 64(8):1195-8. PubMed ID: 15731289
[TBL] [Abstract][Full Text] [Related]
26. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
[TBL] [Abstract][Full Text] [Related]
27. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.
Doyle MK; Rahman MU; Frederick B; Birbara CA; de Vries D; Toedter G; Wu X; Chen D; Ranganath VK; Westerman ME; Furst DE
Rheumatology (Oxford); 2013 Jul; 52(7):1214-9. PubMed ID: 23418046
[TBL] [Abstract][Full Text] [Related]
28. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation.
Cook AD; Louis C; Robinson MJ; Saleh R; Sleeman MA; Hamilton JA
Arthritis Res Ther; 2016 Dec; 18(1):287. PubMed ID: 27908288
[TBL] [Abstract][Full Text] [Related]
29. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
Bergman GJ; Hochberg MC; Boers M; Wintfeld N; Kielhorn A; Jansen JP
Semin Arthritis Rheum; 2010 Jun; 39(6):425-41. PubMed ID: 20223500
[TBL] [Abstract][Full Text] [Related]
30. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
Kirkham BW; Wasko MC; Hsia EC; Fleischmann RM; Genovese MC; Matteson EL; Liu H; Rahman MU
Ann Rheum Dis; 2014 Jan; 73(1):161-9. PubMed ID: 23300117
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
33. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
[TBL] [Abstract][Full Text] [Related]
34. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
35. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
[TBL] [Abstract][Full Text] [Related]
36. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
37. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response.
Matsuyama Y; Okazaki H; Hoshino M; Onishi S; Kamata Y; Nagatani K; Nagashima T; Iwamoto M; Yoshio T; Ohto-Ozaki H; Tamemoto H; Komine M; Sekiya H; Tominaga S; Minota S
Rheumatol Int; 2012 May; 32(5):1397-401. PubMed ID: 21431944
[TBL] [Abstract][Full Text] [Related]
38. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
Stuhlmüller B; Häupl T; Hernandez MM; Grützkau A; Kuban RJ; Tandon N; Voss JW; Salfeld J; Kinne RW; Burmester GR
Clin Pharmacol Ther; 2010 Mar; 87(3):311-21. PubMed ID: 20032971
[TBL] [Abstract][Full Text] [Related]
39. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Huizinga TW; Batalov A; Stoilov R; Lloyd E; Wagner T; Saurigny D; Souberbielle B; Esfandiari E
Arthritis Res Ther; 2017 Mar; 19(1):53. PubMed ID: 28274253
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
